Pharmicell
Stem cell therapeutics for incurable diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | KRW8.0b | Post IPO Equity | |
| Total Funding | 000k | ||
| KRW | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 16 % | 35 % | 18 % | (7 %) | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 14 % | 21 % | 23 % | 23 % | 14 % | 15 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 13 % | 14 % | 19 % | 18 % | 6 % | 10 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 15 % | 11 % | 14 % | 11 % | 12 % | 12 % |
Source: Company filings or news article
Pharmicell is a South Korean biopharmaceutical company that develops, manufactures, and sells stem cell drugs and biochemicals internationally. The company is structured into two main divisions: the Biopharmaceutical Business and the Biochemical Business.
Founded in 1968 and formerly known as FCB Twelve Co., Ltd., the company adopted the name Pharmicell in 2011. A significant milestone was achieved in July 2011, when the company developed the world's first stem cell therapy, Hearticellgram-AMI, which received approval from the Korean FDA. This therapy uses autologous bone marrow-derived mesenchymal stem cells to treat acute myocardial infarction. The company's CEO is Hyun-Soo Kim, whose background in pharmacology and bone marrow transplants at the university level inspired the company's founding. Faced with challenges in securing investment, he established the company to advance stem cell therapeutics and anti-cancer treatments.
The biopharmaceutical division focuses on developing stem cell therapies for a range of conditions. Its pipeline includes treatments for heart disease (Cellgram_AMI), liver disease (Cellgram-LC), erectile dysfunction (Cellgram-ED), and various brain, nerve, pulmonary, and kidney disorders. The company is also developing anticancer immune cell therapeutic vaccines for prostate and ovarian cancer. Beyond therapeutics, this division offers stem cell banking services and develops stem cell-based cosmetics. The cosmetics line, including products under the 'By Pharmicell Lab' brand, leverages stem cell culture media to offer anti-aging and skin rejuvenation benefits.
The biochemical division manufactures and supplies a variety of chemical products. This includes nucleosides and mPEGs, which are active pharmaceutical ingredients. It also produces industrial chemicals such as eco-friendly flame retardants and low dielectric constant materials used in electronic components, notably for AI accelerators. This division serves as a key revenue driver, supplying materials to multinational pharmaceutical and technology companies.
Keywords: stem cell therapy, biopharmaceutical, biochemicals, mesenchymal stem cells, cellgram, hearticellgram-AMI, nucleosides, active pharmaceutical ingredients, stem cell cosmetics, drug development, regenerative medicine, liver cirrhosis treatment, erectile dysfunction therapy, anticancer vaccines, contract manufacturing organization, industrial chemicals, low dielectric constant materials